Evidence map›Paper›PMID 27930718›Full record

ArticlePloS one2016

Seeing the Invisible: Revealing Atrial Ablation Lesions Using Hyperspectral Imaging Approach.

Narine Muselimyan, Luther M Swift, Huda Asfour, Tigran Chahbazian, Ramesh Mazhari, Marco A Mercader, Narine A Sarvazyan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Image-Based Monitoring of Thermal Ablation.Bioengineering (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Narine MuselimyanDepartment of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States of America.
Luther M SwiftDepartment of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States of America.
Huda AsfourDepartment of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States of America.
Tigran ChahbazianStrasbourg Medical University, Strasbourg, France.
Ramesh MazhariDivision of Cardiology, The George Washington University, Medical Faculty Associates, Washington, District of Columbia, United States of America.
Marco A MercaderDivision of Cardiology, The George Washington University, Medical Faculty Associates, Washington, District of Columbia, United States of America.
Narine A SarvazyanDepartment of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States of America.
George Washington University · USUniversité de Strasbourg · FR

Funding

New generation of catheters for treatment of atrial fibrillationR42HL120511 · NHLBI · NOCTURNAL PRODUCT DEVELOPMENT, LLC · PI SARVAZYAN, NARINE · 2016 to 2017
$2.3M
New generation of catheters for treatment of atrial fibrillationR41HL120511 · NHLBI · NOCTURNAL PRODUCT DEVELOPMENT, LLC · PI SARVAZYAN, NARINE · 2014 to 2014
$200k
NHLBI NIH HHS R41 HL120511NHLBI NIH HHS R42 HL120511
6 · The paper itself

Abstract

backgroundCurrently, there are limited means for high-resolution monitoring of tissue injury during radiofrequency ablation procedures.

objectiveTo develop the next generation of visualization catheters that can reveal irreversible atrial muscle damage caused by ablation and identify viability gaps between the lesions.

methodsRadiofrequency lesions were placed on the endocardial surfaces of excised human and bovine atria and left ventricles of blood perfused rat hearts. Tissue was illuminated with 365nm light and a series of images were acquired from individual spectral bands within 420-720nm range. By extracting spectral profiles of individual pixels and spectral unmixing, the relative contribution of ablated and unablated spectra to each pixel was then displayed. Results of spectral unmixing were compared to lesion pathology.

resultsRF ablation caused significant changes in the tissue autofluorescence profile. The magnitude of these spectral changes in human left atrium was relatively small (< 10% of peak fluorescence value), yet highly significant. Spectral unmixing of hyperspectral datasets enabled high spatial resolution, in-situ delineation of radiofrequency lesion boundaries without the need for exogenous markers. Lesion dimensions derived from hyperspectral imaging approach strongly correlated with histological outcomes. Presence of blood within the myocardium decreased the amplitude of the autofluorescence spectra while having minimal effect on their overall shapes. As a result, the ability of hyperspectral imaging to delineate ablation lesions in vivo was not affected.

conclusionsHyperspectral imaging greatly increases the contrast between ablated and unablated tissue enabling visualization of viability gaps at clinically relevant locations. Data supports the possibility for developing percutaneous hyperspectral catheters for high-resolution ablation guidance.

Indexed as

AnimalsCattleDiagnostic ImagingHeart AtriaHumansRadio Waves

Identifiers

PMID27930718
PMCPMC5145191
OpenAlexW2559842168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.